OptimizeRx Corporation
7.17USD
-0.4300 (-5.66%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 1.0M | 71.5M | 92.1M | 109.4M | 96.6M | 107.6M |
| Q1 | 13.7M | 13.0M | 19.7M | 21.9M | 19.8M | — |
| Q2 | 14.0M | 13.8M | 18.8M | 29.2M | 20.5M | — |
| Q3 | 15.1M | 16.3M | 21.3M | 26.1M | 21.6M | — |
| Q4 | -41.8M* | 28.4M* | 32.3M* | 32.2M* | 34.6M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.640 | -1.03 | -1.10 | .270 | .890 | 1.06 |
| Q1 | -.210 | -.370 | -.380 | -.120 | -.030 | — |
| Q2 | -.210 | -.240 | -.220 | .080 | -.040 | — |
| Q3 | -.190 | -.170 | -.500 | .040 | .170 | — |
| Q4 | -.018* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.242* |
| -.004* |
| .264* |
| .412 |
| — |